Skip to content
MARKETS / BALCAO / ZEOX
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Zeo ScientifiX, Inc. ZEOX

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.2M
▲ 12.5% YoY
$-5.5M
$-741,000
In brief

What this company does

The Company’s principal product is Zofin™, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles. The Company was incorporated in the state of Nevada on August 9, 2011, under the name “Bespoke Tricycles Inc.,” changed its name to “Biotech Products Services and Research, Inc.” effective November 4, 2015, to “Organicell Regenerative Medicine, Inc.” effective June 20, 2018 and assumed its current name of “Zeo ScientifiX, Inc.” effective February 20, 2024. Our executive offices are located at 3321 College Avenue, Suite 246, Davie, Florida and our telephone number is (888) 963-7881. As of October 31, 2025, we had 20 full-time employees and no part-time employees.

Written from the business description in Zeo ScientifiX, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 January 2026. Every sentence was checked against that document before publication.

Growth
USD 5.2M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.2 · Net income -5.5
2.5M5.0M-5.0M-10.0M20112013201520172019202120232025
Compound annual growth
−7.1%
+11.2%
+42.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−106 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -103.6% · Net -106.2%
-500%-1000%-1500%20112013201520172019202120232025
ROE
FY2023 · ROE -2156.5%
-1000%-2000%20112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.7
-2M20112013201520172019202120232025

Total assetsUSD 1.5M
EquityUSD -1.4M
CashUSD 221,000.00
Gross debtUSD 243,000.00
Net debtUSD 22,000.00
Current ratio0.33×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
Income tax $B····0.00.00.00.00.00.0·····
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0·−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0····
EPS, diluted $−0.86−0.74−0.99−1.56−0.01−0.020.00−0.01−0.08−0.01−0.010.00−0.00··
Dividend / sh $···············
Payout %···············
ROE %··−2156.5·········−570.8−201.8−88.3
Shares out B0.010.010.010.011.130.940.500.440.110.100.100.15···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 27 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inNevada
Fiscal year endsOctober 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image